Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of ...

Over the last decades, several innovations have advanced the understanding of human biology and diseases. From the development of induced pluripotent stem ...

The Company has been selected to provide an oral presentation featuring clinical data from its ongoing Phase 1 clinical trial of FT819, its off-the-shelf, CD19-targeted, 1XX CAR T-cell product ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf ...

A cell therapy for regenerating broken spinal cord using lab-grown neurons enters human trials for the first time.

Osteogenic differentiation is essential for bone development, metabolism, and repair; however, the underlying regulatory relationships among genes remain poorly understood. To elucidate the ...

A research team led by Associate Professor Makoto Ikeya in the Department of Clinical Application at Kyoto University has ...

A paradigm shift in the way we treat spinal injuries is now in sight, with the world's first regenerative cell therapy being ...

With its wealth of experience, Creative Biolabs stands ready to support global researchers in advancing their iPSC-derived cell therapy studies.

This designation highlights the potential of Cellino’s automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies. Autologous ...

The advent of induced pluripotent stem cells (iPSCs) could be key to addressing this challenge, with iPSCs offering the potential for self-renewal and pluridirectional differentiation. iPSCs can ...

Stem cell therapy shows early promise for treating Parkinson's. Discover who is in the race to bring this breakthrough to ...